Development of new therapy of oral infection and cancer by applying innate immunity network.

应用先天免疫网络开发口腔感染和癌症的新疗法。

• 批准号: 19592309
• 负责人: OKUMURA Kazuhiko
• 金额: $ 2.91万
• 依托单位: Health Sciences University of Hokkaido
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2007
• 资助国家: 日本
• 起止时间: 2007 至 2009
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-19592309/
• 关键词: 自然免疫分子; カセリシジン・ファミリー; hCAP18; LL-37; 口腔感染症; 口腔扁平上皮癌; アポトーシス; ネクローシス; 樹状細胞; 口腔扁平上皮癌細胞; 抗菌ペプチド; 抗腫瘍活性; 抗菌効果; 細胞浸潤能; 細胞遊走能; 基質分解酵素; 癌抑制遺伝子; 自然免疫; 獲得免疫; カテリシジンファミリー; 抗腫瘍効果

We studied the antimicrobial and antitumor effects of various host defense peptides (HDPs) associates with innate immunity. Additionally, we demonstrated the only member of the cathelicidin family identified in humans, as human cationic antimicrobial protein 18 (hCAP18) regulates signal transduction in epithelial cells and squamous cell carcinoma cells. Our results demonstrated that the bacterial killing of hCAP18 was synergistic with defensin and lactobacilluspeptide, as lactacin. In addition, we show that hCAP18 encoded CAMP gene is tumor suppressive activity in human squamous cell carcinoma.

我们研究了与先天免疫相关的多种宿主防御肽（HDPs）的抗菌和抗肿瘤作用。此外，我们证明了在人类中鉴定的cathelicidin家族的唯一成员，因为人阳离子抗菌蛋白18（hCAP 18）调节上皮细胞和鳞状细胞癌细胞中的信号转导。结果表明，hCAP 18与防御素和乳酸杆菌肽具有协同杀菌作用。此外，我们发现hCAP 18编码的CAMP基因在人鳞状细胞癌中具有肿瘤抑制活性。